Eucreas (vildagliptin + metformin) is a new fixed-dose combination treatment for patients inadequately controlled on metformin alone or in patients who are already treated with the components as separate tablets.

Eucreas is available as film-coated tablets containing vildagliptin 50mg plus metformin hydrochloride 850mg or 1000mg.

Eucreas should be given twice daily. Patients receiving vildagliptin and metformin as separate tablets may switch to the equivalent Eucreas tablet; those on metformin alone should be initiated on the strength of Eucreas tablet that matches their current metformin dose.

View Eucreas drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases